Heron Therapeutics (NASDAQ:HRTX) Downgraded to Hold Rating by StockNews.com

StockNews.com lowered shares of Heron Therapeutics (NASDAQ:HRTX) from a buy rating to a hold rating in a research note released on Thursday.

Separately, Needham & Company LLC decreased their target price on Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th.

Heron Therapeutics Trading Up 0.9 %

NASDAQ HRTX opened at $1.07 on Thursday. Heron Therapeutics has a 1 year low of $1.04 and a 1 year high of $3.93. The stock’s 50-day moving average price is $1.77 and its two-hundred day moving average price is $2.47. The company has a market cap of $162.75 million, a PE ratio of -5.89 and a beta of 1.81.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) EPS for the quarter, meeting the consensus estimate of ($0.03). The firm had revenue of $32.81 million during the quarter, compared to analysts’ expectations of $36.40 million. During the same quarter last year, the company posted ($0.17) EPS. Research analysts forecast that Heron Therapeutics will post -0.13 EPS for the current fiscal year.

Institutional Trading of Heron Therapeutics

Several institutional investors have recently made changes to their positions in HRTX. Marshall Wace LLP increased its stake in Heron Therapeutics by 256.2% in the 2nd quarter. Marshall Wace LLP now owns 1,761,051 shares of the biotechnology company’s stock valued at $6,164,000 after buying an additional 1,266,697 shares during the period. Clearline Capital LP grew its holdings in shares of Heron Therapeutics by 48.9% during the 3rd quarter. Clearline Capital LP now owns 2,226,512 shares of the biotechnology company’s stock valued at $4,431,000 after acquiring an additional 731,246 shares in the last quarter. AQR Capital Management LLC increased its stake in shares of Heron Therapeutics by 1,460.9% in the second quarter. AQR Capital Management LLC now owns 607,135 shares of the biotechnology company’s stock worth $2,125,000 after acquiring an additional 568,238 shares during the last quarter. Congress Park Capital LLC increased its stake in shares of Heron Therapeutics by 25.3% in the third quarter. Congress Park Capital LLC now owns 1,978,078 shares of the biotechnology company’s stock worth $3,936,000 after acquiring an additional 399,577 shares during the last quarter. Finally, Squarepoint Ops LLC raised its holdings in shares of Heron Therapeutics by 369.0% during the second quarter. Squarepoint Ops LLC now owns 363,700 shares of the biotechnology company’s stock worth $1,273,000 after acquiring an additional 286,160 shares in the last quarter. 80.01% of the stock is currently owned by institutional investors and hedge funds.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.